Annovis Bio Inc. is a biopharmaceutical company that was founded in 2008 with a mission to develop innovative therapies for neurodegenerative diseases, with a particular focus on Alzheimer's disease and Parkinson's disease. The company was established by Dr. Maria Maccecchini, a scientist with a background in pharmaceutical research and drug development.
Annovis Bio's primary focus is on addressing the underlying mechanisms that contribute to neurodegenerative diseases. The company develops novel drug candidates that target key pathways involved in the progression of these disorders. Their goal is to create treatments that not only alleviate symptoms but also target the root causes of neurodegeneration.
An additional notable aspect of Annovis Bio's operations is its dedication to rigorous scientific research and clinical development. The company conducts preclinical and clinical studies to evaluate the safety and efficacy of its drug candidates, aiming to bring potential therapies to patients in need.
In recent years, Annovis Bio has been advancing its lead drug candidate, ANVS401, through clinical trials. ANVS401 is being evaluated for its potential to target neurotoxic proteins and improve cognitive function in patients with Alzheimer's disease and Parkinson's disease.